Key Points
- Insider sale: BioNTech COO Sierk Poetting sold 50,000 shares on April 22 at an average of $110.56 for $5,528,000 under a pre-arranged Rule 10b5-1 plan, leaving him with 399,387 shares (about $44.16M) and an 11.13% reduction in his ownership.
- Company fundamentals: BNTX opened at $105.56 and was down ~2.8%, with a $26.69B market cap, quarterly EPS of -$0.39 on $1.06B revenue, and negative net margin and return on equity.
- Analyst sentiment and ownership: Ratings are mixed but the consensus is a "Moderate Buy" with a $133.13 price target, and institutional investors hold roughly 15.5% of the stock.
BioNTech SE Sponsored ADR (NASDAQ:BNTX - Get Free Report) COO Sierk Poetting sold 50,000 shares of the firm's stock in a transaction that occurred on Wednesday, April 22nd. The shares were sold at an average price of $110.56, for a total value of $5,528,000.00. Following the completion of the transaction, the chief operating officer owned 399,387 shares of the company's stock, valued at approximately $44,156,226.72. This represents a 11.13% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
BioNTech Stock Down 2.8%
BNTX stock opened at $105.56 on Friday. The company has a quick ratio of 7.49, a current ratio of 7.54 and a debt-to-equity ratio of 0.01. The business has a 50 day moving average price of $97.97 and a two-hundred day moving average price of $101.21. The company has a market cap of $26.69 billion, a price-to-earnings ratio of -20.14 and a beta of 1.58. BioNTech SE Sponsored ADR has a twelve month low of $79.52 and a twelve month high of $124.00.
BioNTech (NASDAQ:BNTX - Get Free Report) last posted its quarterly earnings results on Saturday, February 14th. The company reported ($0.39) earnings per share for the quarter. The company had revenue of $1.06 billion during the quarter. BioNTech had a negative net margin of 38.09% and a negative return on equity of 4.76%. Analysts anticipate that BioNTech SE Sponsored ADR will post -4.41 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of research firms have weighed in on BNTX. Weiss Ratings restated a "sell (d-)" rating on shares of BioNTech in a research note on Wednesday, April 8th. Wall Street Zen downgraded BioNTech from a "hold" rating to a "sell" rating in a research note on Saturday, March 14th. BMO Capital Markets reduced their target price on BioNTech from $143.00 to $128.00 and set an "outperform" rating for the company in a research note on Wednesday, March 11th. Morgan Stanley lifted their target price on BioNTech from $125.00 to $126.00 and gave the stock an "overweight" rating in a research note on Friday, April 10th. Finally, The Goldman Sachs Group reiterated a "buy" rating on shares of BioNTech in a research note on Wednesday, March 11th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, BioNTech currently has an average rating of "Moderate Buy" and a consensus price target of $133.13.
Get Our Latest Research Report on BNTX
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently made changes to their positions in the business. Larson Financial Group LLC boosted its stake in shares of BioNTech by 86.4% during the 4th quarter. Larson Financial Group LLC now owns 274 shares of the company's stock worth $26,000 after acquiring an additional 127 shares during the period. EFG International AG bought a new stake in BioNTech in the 4th quarter valued at $29,000. Caitong International Asset Management Co. Ltd boosted its stake in BioNTech by 520.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 310 shares of the company's stock valued at $30,000 after purchasing an additional 260 shares during the period. Financial Consulate Inc. bought a new stake in BioNTech in the 3rd quarter valued at $36,000. Finally, Huntington National Bank boosted its stake in BioNTech by 1,266.7% in the 3rd quarter. Huntington National Bank now owns 410 shares of the company's stock valued at $40,000 after purchasing an additional 380 shares during the period. 15.52% of the stock is currently owned by institutional investors.
BioNTech Company Profile
(
Get Free Report)
BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.
BioNTech's core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
